INTERRELATION OF TYPES OF REMODELLING OF THE LEFT VENTRICLE WITH OKSIDATIVE STRESS, PHOSPHORUS-CALCIUM AND LIPIDIC EXCHANGE IN END-STAGE RENAL FAILURE

AIM. To ascertain role and analysis of modern concepts of biochemical markers of morphofunctional myocardium and large arteries alterations in patients with end-stage renal failure (ESRF). PATIENTS AND METHODS. A total of 105 patients (57 females and 48 males aged 23-62 years) on hemodialysis participated in the study. The patients were examined clinically with estimation of the levels of parathormone, calcium, phosphorus, adiponectin, homocysteine, leptin, malondialdehyde (MDA) and the activities of catalase and superoxide dismutase (SOD), erythrocytic indexes, serum ferritin and blood transferrin. Echocardiography with Doppler sonography were made on Aloka-4000 unit for an assessment of left ventricular geometry, diastolic and systolic function including intima-media complex thickness (IMC) of carotid and femoral arteries. Therapeutic policy included correction of anemia, arterial hypertension, phosphorus-calcium metabolism. RESULTS. The higher concentrations of parathormone, calcium, phosphorus, homocysteine and leptin correlated with anemia intensity, severity of diastolic and systolic dysfunction and LVH. The higher concentration of MDA and decreased activities of catalase and SOD correlated with the severity of functional changes in the cardiovascular system in examined patients. CONCLUSION. The increase of level of biochemical markers of calcium-phosphorus metabolism, oxidative stress and dyslipidemia in patients with end-stage renal failure, which correlate with cardiovascular system damage level, confirm its important role in the development of cardiovascular complications in ESRF.

chronic kidney disease, cardiovascular diseases, biochemical markers

1. Мухин НА, Моисеев ВС, Кобалава ЖД и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер арх 2004; 6:39-46

2. Coll B, Betriu A, Martinez-Alonso M, Borras M. еt al. Cardiovascular risk factors underestimate atherosclerotic burden in chronic kidney disease: usefulness of non-invasive tests in cardiovascular assessrnent. Nephrol Dial Transplant 2010; 25: 3017-3025

3. Батюшин ММ, Врублевская НС. Клинические проявления поражения почек при хронической сердечной недостаточности. Нефрология 2010; 14(4): 27-30

4. Смирнов АВ. Системный подход к анализу кардиоренальных взаимоотношений как первый шаг на пути к нефрологии формата П4. Нефрология 2011;15(2):11-19

5. Добронравов ВА. Cовременный взгляд на патофизиологию вторичного гиперпаратиреоза: роль фактора роста фибробластов 23 и Klotho. Нефрология 2011; 15(4):11-20

6. Дзгоева ФУ, Гатагонова ТМ, Кадзаева ЗК и др. Гипертрофия левого желудочка в терминальной стадии почечной недостаточности и возможность обратного ее развития в результате коррекции анемии и артериальной гипертензии. Тер арх 2011; 6:42-46

7. Desai AS, Toto R, Jarolim P. et al. Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD. Am J Kidney Dis 2011; 58(5):717-728

8. Park SH, Stenvinkel P, Lindholm B. Cardiovascular biomarkers in chronic kidney disease. J Ren Nutr 2012 Jan; 22(1):120-127

9. Levey AS. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-612

10. Рыбакова МК, Алехин МН, Митьков ВВ. Практическое руководство по ультразвуковой диагностике. Эхокардиография. Видар, М.: 2008: 501

11. Рекомендации ВНОК. Диагностика и лечение ХСН. 3-й пересмотр. Сердечная недостаточность 2010; 11 (1):83-86

12. Parikh NI, Hwang SJ, Larson MG, Levy D, Fox CS. Chronic kidney disease as a predictor of cardiovascular disease (from the Framingham Heart Study). Am J Cardiol 2008; 102: 47–53

13. Смирнов АВ, Волков ММ, Добронравов ВА. Кардиопротективные эффекты D-гормона у больных с хронической болезнью почек: обзор литературы и собственные данные. Нефрология 2009; 13(1) :30-38

14. Fassett RG, Venuthurupalli SK, Gobe GC et al. Biomarkers in chronic kidney disease: a review. Kidney Int 2011 Oct; 80(8):806-821

15. Qasim AN, Rafeek H, Rasania SP. Cardiovascular risk factors and mitral annular calcification in type 2 diabetes. Atherosclerosis 2013 Feb; 226(2):419-424

16. Zoccali C, Mallamaci F. Adiponectin and leptin in chronic kidney disease: causal factors or mere risk markers? J Ren Nutr 2011 Jan; 21(1):87-91

17. Lekawanvijit S, Kompa А, Wang B et al. Cardiorenal Syndrome. The Emerging Role of Protein-Bound Uremic Toxins. Circulation Research 2012; 111: 1470-1483

18. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006; 189: 47–60

19. Guebre-Egziabher F, Bernhard J, Funahashi T et al. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005; 20(1): 129-134

20. Nishimura M, Hashimoto T, Kobayashi H et al. Association of the circulating adiponectin concentration with coronary in-stent restenosis in haemodialysis patients. Nephrol Dial Transplant 2006; 21 (6): 1640-1647

21. Bacchetta J, Boutroy S, Guebre-Egziabher F et al. The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease. Nephrol Dial Transplant 2009; 24(10): 3120-3125

22. Fuerst M, Taylor C, Wright B et al. Inhibition of smooth muscle cell proliferation by adiponectin requires proteolytic conversion to its globular form. J Endocrinol 2012;215:107-117

23. Perna AF, Ingrosso D, Violetti E et al. Hyperhomocysteinemia in uremia – a red flag in a disrupted circuit. Semin Dial 2009; 22: 351–356

24. Kaul S, Zadeh AA, Shah PK. Homocysteine hypothesis for atherothrombotic cardiovascular disease not validated. J Am Coll Cardiol 2006; 48: 914–923

25. Волков ММ, Смирнов АВ. Рентгенологическая оценка кальцификации брюшной аорты у больных с хронической болезнью почек, получающих гемодиализ: частота выявления и ассоциированные факторы. Нефрология 2010; 14(3):37-45

26. McIntyre NJ, Fluck RJ, McIntyre CW et al. Determinants of arterial stiffness in chronic kidney disease stage 3. PLoS One 2013; 8(1):55-64

27. Волков ММ. Биохимические показзатели фосфорнокальциевого обмена у пациентов с хронической болезнью почек 1-5 стадий. Нефрология 2009; 13(3):49-51

28. Spasovski G, Massy Z, Vanholder R. Phosphate metabolism in chronic kidney disease: from pathophysiology to clinical management. Semin Dial 2009; 22: 357–362

29. Дзгоева ФУ, Гатагонова ТМ, Дзугкоева ФС и др. Роль свободнорадикального окисления в развитии сердечнососудистых осложнений при хронической почечной недостаточности. Тер арх 2010;1:51-56

30. Seung-Kwon M, Ju W. systematic review and meta-analysis of randomised controlled trials. BMJ 2013; 346:f10